Diagnostic value of parameters derived from planar MUGA for detecting HFpEF in coronary artery disease patients

Diagnostic value of parameters derived from planar MUGA for detecting HFpEF in coronary artery disease patients

Abstract Background In recent years, heart failure with preserved ejection fraction (HFpEF) has received increasing clinical attention. To investigate the diagnostic value of diastolic function parameters derived from planar gated blood-pool imaging (MUGA) for detecting HFpEF in coronary atheroscler...

Full description

Bibliographic Details
Main Authors:	Qiaozhi Liu, Shuaishuai Zhou, Qi Wu, Ronghua Zuo, Shengjue Xiao, Xiaotong Wang, Ailin Liu, Jie Liu, Hong Zhu, Defeng Pan
Format:	Article
Language:	English
Published:	BMC 2023-01-01
Series:	BMC Cardiovascular Disorders
Subjects:	Planar gated blood-pool imaging Heart failure with preserved ejection fraction Echocardiography Coronary artery disease Left ventricular end-diastolic pressure
Online Access:	https://doi.org/10.1186/s12872-023-03061-w

Similar Items

Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
by: Ajmer Singh, et al.
Published: (2018-01-01)

Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations
by: Dzhioeva O, et al.
Published: (2020-08-01)

Left atrial conduit flow rate at baseline and during exercise: an index of impaired relaxation in HFpEF patients
by: Paolo N. Marino, et al.
Published: (2021-10-01)

Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study
by: Artem Ovchinnikov, et al.
Published: (2022-07-01)

Similarities and Differences Between HFmrEF and HFpEF
by: Peixin Li, et al.
Published: (2021-09-01)

Non-invasive assessment of HFpEF in mouse models: current gaps and future directions
by: María Villalba-Orero, et al.
Published: (2022-10-01)

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes
by: Alberto Palazzuoli, et al.
Published: (2021-05-01)

The relationship between ambulatory arterial stiffness index and left ventricular diastolic dysfunction in HFpEF: a prospective observational study
by: Hanwen Zhang, et al.
Published: (2022-06-01)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
by: Manuel Martínez-Sellés, et al.
Published: (2022-05-01)

ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction
by: Antje Schauer, et al.
Published: (2020-10-01)

Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension
by: M. A. Manukyan, et al.
Published: (2021-11-01)

Webtool to enhance the accuracy of diagnostic algorithms for HFpEF: a prospective cross‐over study
by: Jerremy Weerts, et al.
Published: (2023-12-01)

Contribution of Global and Regional Longitudinal Strain for Clinical Assessment of HFpEF in Coronary and Hypertensive Patients
by: Gheorghe Stoichescu-Hogea, et al.
Published: (2021-12-01)

Diastolic dysfunction and sex-specific progression to HFpEF: current gaps in knowledge and future directions
by: A. M. L. N. van Ommen, et al.
Published: (2022-12-01)

HFpEF as systemic disease, insight from a diagnostic prediction model reminiscent of systemic inflammation and organ interaction in HFpEF patients
by: Rong Zhou, et al.
Published: (2024-03-01)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
by: Paolo Morfino, et al.
Published: (2022-08-01)

Prognostic Value of Right Ventricular 3D Speckle-Tracking Strain and Ejection Fraction in Patients With HFpEF
by: Yuanli Meng, et al.
Published: (2021-06-01)

Association of Plasma Myeloperoxidase with Inflammation and Diabetic status in HFpEF
by: Sibille Lejeune, et al.
Published: (2023-02-01)

Predictors and Mortality for Worsening Left Ventricular Ejection Fraction in Patients With HFpEF
by: Liling Chen, et al.
Published: (2022-02-01)

Different determinants of exercise capacity in HFpEF compared to HFrEF
by: Arlind Batalli, et al.
Published: (2017-04-01)

Obesity and HFpEF
by: Francesco Clemenza, et al.
Published: (2022-07-01)

Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
by: Yanhong Guo, et al.
Published: (2022-11-01)

Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding
by: Steven J. Simmonds, et al.
Published: (2020-01-01)

Leucine Supplementation Improves Diastolic Function in HFpEF by HDAC4 Inhibition
by: Paula Ketilly Nascimento Alves, et al.
Published: (2023-11-01)

To determine the correlation between echocardiographic diastolic parameters and invasively measured left ventricular end diastolic pressure in patients with heart failure with preserved ejection fraction- an observational, descriptive study. (CEAL-HFpEF study)
by: Awadhesh kumar Sharma, et al.
Published: (2021-07-01)

Characteristics, prognosis, and treatment response in HFpEF patients with high vs. normal ejection fraction
by: Jun Gu, et al.
Published: (2022-09-01)

Is excessive ventricular irregularity predictive of rehospitalization in patients with permanent AF and HFpEF?
by: Corentin Chaumont, et al.
Published: (2023-06-01)

Impact of Myocardial Energy Expenditure and Diastolic Dysfunction on One Year Outcome Patients With HFpEF
by: Yu Wang, et al.
Published: (2022-04-01)

Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF)
by: María Valero-Muñoz, et al.
Published: (2022-08-01)

Ubiquitin‐proteasome‐system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF
by: Volker Adams, et al.
Published: (2021-08-01)

The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles
by: Michiel T.H.M. Henkens, et al.
Published: (2022-06-01)

A potential role of autophagy-mediated vascular senescence in the pathophysiology of HFpEF
by: Fernanda Sanhueza-Olivares, et al.
Published: (2022-11-01)

Vascular dysfunction in HFpEF: Potential role in the development, maintenance, and progression of the disease
by: Andrea Saavedra-Alvarez, et al.
Published: (2022-12-01)

Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation
by: Linjuan Guo, et al.
Published: (2023-09-01)

Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients
by: Camilla Hage, et al.
Published: (2020-08-01)

The pK56M ICAM1 HFpEF risk variant and inflammatory biomarkers
by: Pedro Giro, et al.
Published: (2023-12-01)

Clinical efficacy of sacubitril/valsartan in treatment of acute STEMI complicated with HFpEF
by: Kong Can, Peng Hui
Published: (2023-06-01)

Leucine Supplementation Prevents the Development of Skeletal Muscle Dysfunction in a Rat Model of HFpEF
by: Paula Ketilly Nascimento Alves, et al.
Published: (2024-03-01)

Enhanced central sympathetic tone induces heart failure with preserved ejection fraction (HFpEF) in rats
by: Shyam S. Nandi, et al.
Published: (2023-12-01)

Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
by: Wenchao Zhang, et al.
Published: (2021-01-01)